Get started
Author

Jocelyn Staunton

Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition
2018 · Siegfried H. Reich, Paul A. Sprengeler, et al. · Journal of Medicinal Chemistry · 188
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase
2020 · Justin T. Ernst, Peggy A. Thompson, et al. · Journal of Medicinal Chemistry · 147
INT131: A Selective Modulator of PPARγ
2009 · Alykhan Motani, Zhulun Wang, et al. · Journal of Molecular Biology · 125
The Scaling of Carbon Dioxide Release and Respiratory Water Loss in Flying Fruit Flies (Drosophila Spp.)
2000 · Fritz-Olaf Lehmann, Michael H. Dickinson, et al. · Journal of Experimental Biology · 68
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A
2020 · Peggy A. Thompson, Boreth Eam, et al. · Molecular Cancer Therapeutics · 50
Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors
2021 · Adina Gerson-Gurwitz, Nathan P. Young, et al. · Frontiers in Oncology · 48
Hit-to-Lead Optimization and Discovery of 5-((5-([1,1′-Biphenyl]-4-yl)-6-chloro-1 H -benzo[ d ]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase
2017 · Ping Lan, F. Anthony Romero, et al. · Journal of Medicinal Chemistry · 28
eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)
2015 · Kevin R. Webster, Vikas K Goel, et al. · Blood · 27
Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity
2009 · Katayoun Jessen, Shunyou Wang, et al. · Molecular Cancer Therapeutics · 25
Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C
2023 · Snahel Patel, Barun Bhhatarai, et al. · Cancer Research · 21
Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.
2011 · Katti Jessen, Linda Kessler, et al. · Molecular Cancer Therapeutics · 17
Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer
2012 · Shunyou Wang, Lucy Lan, et al. · Cancer Research · 16
Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies
2017 · Peggy A. Thompson, Boreth Eam, et al. · Blood · 13
Abstract 5948: FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance
2024 · Yan Wang, Richard M. Neve, et al. · Cancer Research · 7
Abstract 4501: INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer
2011 · Katayoun A. Jessen, Linda Kessler, et al. · Cancer Research · 7
Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity
2017 · Kevin R. Webster, Vikas K. Goel, et al. · Cancer Research · 5
Abstract 2698: eFT226, a potent and selective inhibitor of eIF4A, is efficacious in preclinical models of lymphoma
2019 · Peggy A. Thompson, Boreth Eam, et al. · Cancer Research · 4
Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers
2019 · Peggy A Thompson, Nathan P Young, et al. · Molecular Cancer Therapeutics · 3
Abstract LB-068: Tomivosertib (eFT508), a potent and highly selective inhibitor of MNK1 and MNK2, enhances CAR T cell activity through modulating T cell differentiation
2019 · Vikas K. Goel, Rajesh K. Sharma, et al. · Cancer Research · 3
Abstract 5546: eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, regulates T-cell differentiation promoting an antitumor immune response
2018 · Rajesh K. Sharma, Vikas K. Goel, et al. · Cancer Research · 3
Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade
2017 · Kevin R. Webster, Vikas K. Goel, et al. · Cancer Research · 3
Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer
2011 · Shunyou Wang, Katti Jessen, et al. · Cancer Research · 3
Abstract 1302: Targeting hormone receptor-dependent cancers with potent, selective and orally-available small molecule inhibitors of eIF4E
2019 · Gary G. Chiang, Gregory S. Parker, et al. · Cancer Research · 2
Abstract DDT02-05: eFT226: A selective and highly potent inhibitor of eukaryotic initiation factor 4A (eIF4A), a novel approach for the treatment of cancer
2018 · Siegfried H. Reich, Peggy A. Thompson, et al. · Cancer Research · 2
Abstract 5949: The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC
2024 · Yan Wang, Allison Roberts, et al. · Cancer Research · 1
Works count: 45
Citation count: 818
H-index: 13
I10-index: 13
Year
Topic
Type